Medical Center Health Care Ltd.

The research team at Medical Center Health Care Ltd. is evaluating innovative treatments to lower the risk of heart failure and cardiovascular death, focusing on a combination of baxdrostat and dapagliflozin in patients at elevated risk.

• Prevention of heart failure
• Evaluation of baxdrostat/dapagliflozin combination
• Assessment of cardiovascular risk reduction
• Study of heart failure outcomes

This work contributes to the broader effort to improve cardiovascular health across Europe, leveraging the expertise of three investigators at the Petrich clinic.

In the rheumatology department, researchers are testing a new oral agent, AP1189, together with methotrexate to enhance treatment response in patients newly diagnosed with rheumatoid arthritis.

• Early rheumatoid arthritis treatment
• Combination therapy with AP1189
• Methotrexate optimization
• Reducing inflammation in autoimmune disease

The study aims to provide a faster disease‑modifying approach for individuals who have not yet received disease‑modifying anti‑rheumatic drugs.

Clinical investigations are assessing advanced inhaled therapies, including a triple‑component inhaler (budesonide/glycopyrronium/formoterol), as well as the biologic tozorakimab, to improve lung function and curb exacerbations in patients with severe asthma and COPD.

• Severe asthma management
• COPD exacerbation reduction
• Triple inhaler therapy assessment
• Tozorakimab add‑on study

These trials seek to offer better symptom control for individuals whose respiratory disease remains inadequately managed by standard care.